The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide

K. G. Thusu, F. C. Morin, J. A. Russell, Robin H Steinhorn

Research output: Contribution to journalArticle

91 Citations (Scopus)

Abstract

We investigated the effect of zaprinast (M and B 22948), a specific cGMP phosphodiesterase inhibitor, on pulmonary arteries isolated from lambs with persistent pulmonary hypertension following prenatal ligation of the ductus arteriosus. Relaxations to sodium nitroprusside, which donates nitric oxide inside the smooth muscle cell, were significantly decreased in pulmonary arteries from ligated lambs. Pretreatment with 3 x 10-5 M zaprinast restored them to levels close to those observed in untreated arteries from control animals. Further studies in intact newborn lambs were then conducted under three experimental conditions: (1) NO inhalation at 6 ppm, (2) zaprinast infusion at 0.05 mg/kg/min, and (3) combination therapy of zaprinast infusion in addition to inhaled NO at 6 ppm. Combined therapy with NO and zaprinast decreased the pulmonary artery pressure (34.3 ± 3%) and pulmonary vascular resistance (64 ± 7%) and increased pulmonary blood flow (88 ± 34%) and postductal Pa(O2) (287 ± 34%) to a significantly greater extent than NO alone, zaprinast alone, or the sum of these two responses, indicating a true synergistic effect. Zaprinast pretreatment also markedly increased the duration of pulmonary vasodilation to nitric oxide. There was no effect on systemic blood pressure with the combined therapy. We conclude that zaprinast pretreatment significantly enhances the effect of sodium nitroprusside on isolated pulmonary arteries, as well the effect of inhaled NO at 6 ppm in newborn lambs with persistent pulmonary hypertension. We speculate that phosphodiesterase inhibition may increase the response rate to NO or allow the use of much lower inhaled concentrations of NO.

Original languageEnglish (US)
Pages (from-to)1605-1610
Number of pages6
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume152
Issue number5 I
StatePublished - 1995
Externally publishedYes

Fingerprint

Phosphodiesterase Inhibitors
Nitric Oxide
Pulmonary Artery
Nitroprusside
Pulmonary Hypertension
zaprinast
Ductus Arteriosus
Lung
Phosphoric Diester Hydrolases
Vasodilation
Vascular Resistance
Inhalation
Smooth Muscle Myocytes
Ligation
Therapeutics
Arteries
Blood Pressure
Pressure

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Thusu, K. G., Morin, F. C., Russell, J. A., & Steinhorn, R. H. (1995). The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide. American Journal of Respiratory and Critical Care Medicine, 152(5 I), 1605-1610.

The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide. / Thusu, K. G.; Morin, F. C.; Russell, J. A.; Steinhorn, Robin H.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 152, No. 5 I, 1995, p. 1605-1610.

Research output: Contribution to journalArticle

Thusu, KG, Morin, FC, Russell, JA & Steinhorn, RH 1995, 'The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide', American Journal of Respiratory and Critical Care Medicine, vol. 152, no. 5 I, pp. 1605-1610.
Thusu, K. G. ; Morin, F. C. ; Russell, J. A. ; Steinhorn, Robin H. / The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide. In: American Journal of Respiratory and Critical Care Medicine. 1995 ; Vol. 152, No. 5 I. pp. 1605-1610.
@article{03b0f456555a456c819e3375d2847273,
title = "The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide",
abstract = "We investigated the effect of zaprinast (M and B 22948), a specific cGMP phosphodiesterase inhibitor, on pulmonary arteries isolated from lambs with persistent pulmonary hypertension following prenatal ligation of the ductus arteriosus. Relaxations to sodium nitroprusside, which donates nitric oxide inside the smooth muscle cell, were significantly decreased in pulmonary arteries from ligated lambs. Pretreatment with 3 x 10-5 M zaprinast restored them to levels close to those observed in untreated arteries from control animals. Further studies in intact newborn lambs were then conducted under three experimental conditions: (1) NO inhalation at 6 ppm, (2) zaprinast infusion at 0.05 mg/kg/min, and (3) combination therapy of zaprinast infusion in addition to inhaled NO at 6 ppm. Combined therapy with NO and zaprinast decreased the pulmonary artery pressure (34.3 ± 3{\%}) and pulmonary vascular resistance (64 ± 7{\%}) and increased pulmonary blood flow (88 ± 34{\%}) and postductal Pa(O2) (287 ± 34{\%}) to a significantly greater extent than NO alone, zaprinast alone, or the sum of these two responses, indicating a true synergistic effect. Zaprinast pretreatment also markedly increased the duration of pulmonary vasodilation to nitric oxide. There was no effect on systemic blood pressure with the combined therapy. We conclude that zaprinast pretreatment significantly enhances the effect of sodium nitroprusside on isolated pulmonary arteries, as well the effect of inhaled NO at 6 ppm in newborn lambs with persistent pulmonary hypertension. We speculate that phosphodiesterase inhibition may increase the response rate to NO or allow the use of much lower inhaled concentrations of NO.",
author = "Thusu, {K. G.} and Morin, {F. C.} and Russell, {J. A.} and Steinhorn, {Robin H}",
year = "1995",
language = "English (US)",
volume = "152",
pages = "1605--1610",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "5 I",

}

TY - JOUR

T1 - The cGMP phosphodiesterase inhibitor zaprinast enhances the effect of nitric oxide

AU - Thusu, K. G.

AU - Morin, F. C.

AU - Russell, J. A.

AU - Steinhorn, Robin H

PY - 1995

Y1 - 1995

N2 - We investigated the effect of zaprinast (M and B 22948), a specific cGMP phosphodiesterase inhibitor, on pulmonary arteries isolated from lambs with persistent pulmonary hypertension following prenatal ligation of the ductus arteriosus. Relaxations to sodium nitroprusside, which donates nitric oxide inside the smooth muscle cell, were significantly decreased in pulmonary arteries from ligated lambs. Pretreatment with 3 x 10-5 M zaprinast restored them to levels close to those observed in untreated arteries from control animals. Further studies in intact newborn lambs were then conducted under three experimental conditions: (1) NO inhalation at 6 ppm, (2) zaprinast infusion at 0.05 mg/kg/min, and (3) combination therapy of zaprinast infusion in addition to inhaled NO at 6 ppm. Combined therapy with NO and zaprinast decreased the pulmonary artery pressure (34.3 ± 3%) and pulmonary vascular resistance (64 ± 7%) and increased pulmonary blood flow (88 ± 34%) and postductal Pa(O2) (287 ± 34%) to a significantly greater extent than NO alone, zaprinast alone, or the sum of these two responses, indicating a true synergistic effect. Zaprinast pretreatment also markedly increased the duration of pulmonary vasodilation to nitric oxide. There was no effect on systemic blood pressure with the combined therapy. We conclude that zaprinast pretreatment significantly enhances the effect of sodium nitroprusside on isolated pulmonary arteries, as well the effect of inhaled NO at 6 ppm in newborn lambs with persistent pulmonary hypertension. We speculate that phosphodiesterase inhibition may increase the response rate to NO or allow the use of much lower inhaled concentrations of NO.

AB - We investigated the effect of zaprinast (M and B 22948), a specific cGMP phosphodiesterase inhibitor, on pulmonary arteries isolated from lambs with persistent pulmonary hypertension following prenatal ligation of the ductus arteriosus. Relaxations to sodium nitroprusside, which donates nitric oxide inside the smooth muscle cell, were significantly decreased in pulmonary arteries from ligated lambs. Pretreatment with 3 x 10-5 M zaprinast restored them to levels close to those observed in untreated arteries from control animals. Further studies in intact newborn lambs were then conducted under three experimental conditions: (1) NO inhalation at 6 ppm, (2) zaprinast infusion at 0.05 mg/kg/min, and (3) combination therapy of zaprinast infusion in addition to inhaled NO at 6 ppm. Combined therapy with NO and zaprinast decreased the pulmonary artery pressure (34.3 ± 3%) and pulmonary vascular resistance (64 ± 7%) and increased pulmonary blood flow (88 ± 34%) and postductal Pa(O2) (287 ± 34%) to a significantly greater extent than NO alone, zaprinast alone, or the sum of these two responses, indicating a true synergistic effect. Zaprinast pretreatment also markedly increased the duration of pulmonary vasodilation to nitric oxide. There was no effect on systemic blood pressure with the combined therapy. We conclude that zaprinast pretreatment significantly enhances the effect of sodium nitroprusside on isolated pulmonary arteries, as well the effect of inhaled NO at 6 ppm in newborn lambs with persistent pulmonary hypertension. We speculate that phosphodiesterase inhibition may increase the response rate to NO or allow the use of much lower inhaled concentrations of NO.

UR - http://www.scopus.com/inward/record.url?scp=0028808770&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028808770&partnerID=8YFLogxK

M3 - Article

C2 - 7582302

AN - SCOPUS:0028808770

VL - 152

SP - 1605

EP - 1610

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 5 I

ER -